Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

Start Date01 Jul 2024

Sponsor / Collaborator

Iperboreal Pharma SRL

ACTRN12624000504516 / Not yet recruitingNot ApplicableIIT

Effect of levocarnitine supplementation on quality of life amongst patients on maintenance haemodialysis for end stage renal disease

Start Date01 May 2024

Sponsor / Collaborator-

IRCT20240129060837N1 / RecruitingPhase 3IIT

Efficacy of L-carnitine in decrease of liver enzymes and liver fat content in patients with non-alcoholic fatty liver disease

Start Date24 Mar 2024

Sponsor / Collaborator-

100 Clinical Results associated with Levocarnitine

100 Translational Medicine associated with Levocarnitine

100 Patents (Medical) associated with Levocarnitine

7,179

Literatures (Medical) associated with Levocarnitine

01 Dec 2024·Applied microbiology and biotechnology

Biosynthesis of Bt-Ag2O nanoparticles using Bacillus thuringiensis and their pesticidal and antimicrobial activities

Article

Author: Liu, Wenzhuo ; Wang, Yirong ; Xu, Caijiayi ; Cui, Sufen ; Ge, Jiajia ; Hu, Jianzhong

Abstract:

Nanosilver oxide exhibits strong antibacterial and photocatalytic properties and has shown great application potential in food packaging, biochemical fields, and other fields involving diseases and pest control. In this study, Ag2O nanoparticles were synthesized using Bacillus thuringiensis (Bt-Ag2O NPs). The physicochemical characteristics of the Bt-Ag2O NPs were analyzed by UV‒vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscope (SEM), inductively coupled plasma emission spectrometry (ICP), high-resolution transmission electron microscopy (HR-TEM), and zeta potential. The phis-chemical characterization revealed that the Bt-Ag2O NPs are in spherical shape with the small particle size (18.24 nm), high crystallinity, well dispersity, and stability. The biopesticidal and antifungal effects of Bt-Ag2O NPs were tested against Tribolium castaneum, Aspergillus flavus, and Penicillium chrysogenum. The survival, growth, and reproduction of tested pests and molds were significantly inhibited by Bt-Ag2O NPs in a dose-dependent manner. Bt-Ag2O NPs showed higher pesticidal activities against T. castaneum than Bt and commercial Ag2O NPs. The LC50 values of Bt, Ag2O NPs, and Bt-Ag2O NPs were 0.139%, 0.072%, and 0.06% on day 14, respectively. The Bt-Ag2O NPs also showed well antifungal activities against A. flavus and P. chrysogenum, while it resulted a small inhibition zone than commercial Ag2O NPs did. In addition, A. flavus showed much more sensitive to Bt-Ag2O NP treatments, compared to P. chrysogenum. Our results revealed that Bt-Ag2O NPs synthesized using B. thuringiensis could act as pesticides and antifungal agents in stored-product fields.

Key points:

• Bt-Ag2O NPs could be synthesized using Bacillus thuringiensis (Bt).• The NPs showed a high degree of crystallinity, spherical shape, and small particle size.• The NPs also showed excellent insecticidal and antifungal activity.

01 Jun 2024·Food chemistry

A simple strategy for d/l-carnitine analysis in food samples using ion mobility spectrometry and theoretical calculations

Article

Author: Zhang, Manli ; Zou, Ying ; Wu, Fangling ; Ding, Chuan-Fan ; Liu, Cong ; Zhang, Di ; Chi, Chaoxian

This work presents a straightforward approach to the separation d/l-carnitine (d/l-Carn) using ion mobility-mass spectrometry (IM-MS) and theoretical calculations. Natamycin (Nat) was used as separation reagent to interact with the Carn, metal ions (G) were employed as ligand, the resultant ternary complexes [d/l-Carn + Nat + G]⁺ were observed experimentally. IM-MS results revealed that d/l-Carn could be baseline separated via complex formation using Li⁺, Na⁺, K⁺, Rb⁺, and Cs⁺, with a maximum peak separation resolution (R_p-p) of 2.91; Theoretical calculations were performed to determine the optimal conformations of [d/l-Carn + Nat + Li/K]⁺, and the predicted collisional cross section values were consistent with the experimental values. Conformational analysis was used to elucidate the enantiomeric separation of d/l-Carn at the molecular level via the formation of ternary complexes. Furthermore, quantitative analyses for the determination of the enantiomers were established with effective linearity and acceptable sensitivity. Finally, the proposed method was successfully applied in the determination of d/l-Carn in food samples.

01 May 2024·Meat science

Carnobacterium maltaromaticum as bioprotective culture against spoilage bacteria in ground meat and cooked ham

Article

Author: Pirard, Barbara ; Daube, Georges ; Gemmi, Céline ; Antoine, Céline ; Clinquart, Antoine ; de Andrade Cavalari, Caroline Maria ; Imazaki, Pedro Henrique ; de Macedo, Renata Ernlund Freitas ; Vanleyssem, Raphael ; Lebrun, Sarah ; Crevecoeur, Sébastien

This study assessed the bioprotective effect of Carnobacterium maltaromaticum (CM) against Pseudomonas fluorescens (PF) and Brochothrix thermosphacta (BT) in ground beef and sliced cooked ham stored in high- and low-oxygen-modified atmospheres (66/4/30% O₂/N₂/CO₂ and 70/30% N₂/CO_2, respectively). Both meat products were inoculated with CM, PF, and BT individually or in combination and stored for 7 days (3 days at 4 °C + 4 days at 8 °C) for ground beef and 28 days (10 days at 4 °C + 18 days at 8 °C) for sliced cooked ham. Each food matrix was assigned to 6 treatments: NC (no bacterial inoculation, representing the indigenous bacteria of meat), CM, BT, PF, CM + BT, and CM + PF. Bacterial growth, pH, instrumental color, and headspace gas composition were assessed during storage. CM counts remained stable from inoculation and throughout the shelf-life. CM reduced the population of inoculated and indigenous spoilage bacteria, including BT, PF, and enterobacteria, and showed a negligible impact on the physicochemical quality parameters of the products. Furthermore, upon simulating the shelf-life of ground beef and cooked ham, a remarkable extension could be observed with CM. Therefore, CM could be exploited as a biopreservative in meat products to enhance quality and shelf-life.

News (Medical) associated with Levocarnitine

16 Oct 2023

·www.prnewswire.com

Native Pet Expands Its Growing Portfolio with the Launch of The Daily, An All-In-One Premium Supplement

An everyday product formulated to enhance your dog's daily diet and make a real difference in their health ST. LOUIS, Oct. 16, 2023 /PRNewswire/ -- Native Pet, a leading pet supplement company, announced today the addition of its most powerful and advanced product yet, The Daily. Continuing to challenge the industry, the launch of The Daily lives up to The Native Pet Pact, the brand's unwavering commitment to making a real difference in your pets' health. After two years of development, The Daily comes to market offering a science-backed, everyday solution for your dog's well-being using only the highest-quality and most efficacious ingredients. Continue Reading An everyday product formulated to enhance your dog’s daily diet and make a real difference in their health. "After years of research and development, we're thrilled to introduce The Daily," said Dan Schaefer, CEO and co-founder of Native Pet. "This all-in-one supplement is the first of its kind, packing all the powerful ingredients your dog needs into one tasty and science-backed scoop. Since we know kibble only goes so far, we created The Daily to fit seamlessly into your pet's daily routine and support them through all phases of their tail-wagging lives." Offering a solution for a category composed of mostly soft chews, The Daily's unique powder format ensures the integrity of the active ingredients and the highest level of efficacy for dogs. The new super supplement was formulated with the cleanest label possible, providing real, whole-food ingredients, zero additives or fillers, and the highest number of active ingredients on the market. Pat Barron, Native Pet COO and co-founder added, "We worked hand-in-hand with a team of vet nutritionists, veterinarians, and food scientists, and we're proud to introduce this everyday wellness supplement to support the most common ailments in canine health. We are committed to formulating only the very best products for our pets, which means developing proprietary formulas and hand-selecting ingredients." Barron further explains, "When formulating The Daily, we tapped into powerful active ingredients with Probiotics, L-Carnitine, and Zinc along with more familiar ingredients like Goat Milk, Bone Broth, and Pumpkin to ensure we're making the greatest impact for canine health and wellness." With 11 benefits in just one tasty scoop, The Daily's powerful blend of ingredients work together to support energy utilization, skin and coat health, mobility, gut health, and beyond. The launch of The Daily not only marks an exciting milestone for the brand portfolio, but also solidifies the demand for wider accessibility to Native Pet's products. The brand can now be found in nearly 2,000 retail locations, including 600 Target stores and over 1,000 Petco Pet Care Centers nationwide. Native Pet's continued partnership with Target and expansion into Petco further cements the brand as a leader in the growing market category and supports pet parents everywhere in prioritizing their dogs' health. The Daily is now available online at nativepet.com, Chewy, Amazon, and select Target stores. For more information, visit nativepet.com or follow @nativepet on Instagram and TikTok. About Native Pet Native Pet is committed to developing proprietary formulas and formats, offering only the best, most innovative supplements to directly benefit the health of pets. In an industry that has never prioritized the health of our pets, Native Pet is redefining the bar and holds true to its motto that "we're the voice of our pets and it's our mission to give our fur babies the best lives. Because our love language is dog, and dog is our native tongue." Media Contact [email protected] SOURCE Native Pet

10 Oct 2023

·www.prnewswire.com

American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, "AP" Rated, and Therapeutically Equivalent to Carnitor®¹

SHIRLEY, N.Y., Oct. 10, 2023 /PRNewswire/ -- American Regent announces the release and availability of Levocarnitine Injection, USP, FDA-approved, "AP" rated, and therapeutically equivalent to Carnitor®. Levocarnitine is indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency, and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis. Continue Reading American Regent announces the release and availability of Levocarnitine Injection, USP. Tweet this Levocarnitine Injection is supplied as a 5 mL single-dose vial, with a strength of 1 gram/5 mL (200 mg/mL), and as a 20 mL single-dose vial, with a strength of 4 grams/20 mL (200 mg/mL) "We are pleased to make this crucial medication available to patients who need it. We are equally pleased to add Levocarnitine Injection to our robust line of products, which are formulated, filled, and finished at our US-based manufacturing facilities," stated Joann Gioia, Vice President and Chief Commercial Officer at American Regent, Inc. This product is available for immediate shipment. Customers can order Levocarnitine Injection, USP, through their wholesaler/distributor, or by contacting our Customer Support Group at 1-800-645-1706. See the following Important Safety Information, in addition to the product's Full Prescribing Information. For additional information, please visit . All trademarks are the property of their respective owners. References: 1. Orange book: Approved drug products with therapeutic equivalence evaluations. U.S. Food & Drug Administration. . Accessed April 27, 2023. PP-LI-US-0006 Levocarnitine Injection, USP For intravenous use only INDICATIONS AND USAGE For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS None known. WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following levocarnitine administration, mostly in patients with end-stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of levocarnitine. If a severe hypersensitivity reaction occurs, discontinue levocarnitine treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction. PRECAUTIONS General The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide, since these metabolites are normally excreted in the urine. Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments. Pregnancy There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Nursing Mothers Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment. ADVERSE REACTIONS Clinical Trials Experience Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. Postmarketing Experience The following adverse reactions have been reported: Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported. Hypersensitivity reactions: Anaphylaxis, laryngeal edema, and bronchospasm. For additional safety information, please see Full Prescribing Information. You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting or calling 1-800-FDA-1088. REF 1593 11/2022 You are encouraged to report adverse drug events (ADEs) to American Regent: T 1.800.734.9236; E [email protected]; F 1.610.650.0170 ADEs may also be reported to the FDA: 1.800.FDA.1088 or Medical Information: T 1.888.354.4855 (9:00 am–5:00 pm Eastern Time, Monday–Friday) medical information outside of normal business hours that cannot wait until the next business day, please call 1.877.845.6371 About American Regent American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy. American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future. Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need. For more information, please visit . About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." For more information, please visit: . All trademarks are the property of their respective owners. Reference: 1. Orange book: Approved drug products with therapeutic equivalence evaluations. US Food & Drug Administration. Accessed April 27, 2023. SOURCE American Regent Inc

Drug Approval

05 Oct 2023

·www.prnewswire.com

Bizz Energy Is a Clean, Mean Way to Beat the Modern Midday Slump

The Energy Drink Formula Unleashes Unique Levels of Energy Whilst Avoiding Sugar Crashes and Unhealthy Ingredients FORT LAUDERDALE, Fla., Oct. 5, 2023 /PRNewswire/ -- The modern, remote-first work world may not have a consistent nine-to-five rhythm anymore. But that doesn't change the fact that people are still putting a lot of time into working their jobs. The Bureau of Labor Statistics reports that the average American worker clocks in at just over eight hours of labor per day (8.01, to be precise). That means, no matter when those work hours take place, they're going to extend over a significant portion of an individual's daily schedule. It also means it will involve a slump in energy and productivity at some point along the way. "Midday slumps may not always happen in the early afternoon anymore," says Gavin Jacono, founder of Bizz Energy, "But they happen at some point — and on a regular basis. If you start work at four in the morning, chances are you're going to lag after breakfast or in the late morning. If you start at noon, you'll feel tired before dinner." Northwestern Medicine points out that the biggest reason for this energy slump is that it's a predictable part of every individual's circadian cycle. However, the medical site adds that things like sleep disorders, stress, and even poor eating habits can also contribute to a slowdown in the middle of the workday. When that happens, many people turn to energy drinks as a solution — but Jacono points out that traditional energy drink formulas don't really solve the problem. "Those classic formulas use sugar, high fructose corn syrup, or aspartame. They give you a quick boost, but it's often followed by a crash — usually before your work day ends, which only means you're kicking the productivity issue down the road. And your body has to work through all of those unhealthy chemicals and additives, too. That's why we created Bizz Energy. To turn unhealthy, short-term energy drinks into healthy, long-term productivity and health solutions." Bizz Energy replaces unwanted ingredients with healthy alternatives. Each 12 oz can contains a clean shot of 200 mg of caffeine along with a punchy nutritional combination called the SuperTurk® blend. This includes an innovative soluble form of Turkesterone along with creatine, essential amino acids, L-citrulline, L-theanine, L-carnitine, niacin, and biotin. The result of this revolutionary combination is an energy drink that doubles as a nutritional supplement. It helps boost energy without a sugar crash while also stimulating metabolism and helping build muscle and strength. This makes it a clean, mean way to beat a midday slump — no matter when it might take place. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy

100 Deals associated with Levocarnitine

External Link

KEGG	Wiki	ATC	Drug Bank
D02176	Levocarnitine	A16AA01	DB00583

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Diseases	IT	Alfasigma SpA	18 May 2015
Shock, Septic	IT	Alfasigma SpA	18 May 2015
Cardiovascular Diseases	CN	Leadiant Biosciences, Inc.	31 Dec 1999
Metabolism, Inborn Errors	IE	Shire Pharmaceutical Development Ltd.	23 Oct 1996
Carnitine palmitoyltransferase deficiency	NL	Sigma-Tau Industrie Farmaceutiche Riunite SpA	03 Feb 1986
Systemic Carnitine Deficiency	US	Leadiant Biosciences, Inc.	27 Dec 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	EG	Tanta University	05 Mar 2023
Pain	Phase 3	EG	Tanta University	05 Mar 2023
Rheumatoid Arthritis	Phase 3	EG	Tanta University	05 Mar 2023
Heart Failure	Phase 3	CN	Lee's Pharmaceutical Holdings Ltd.	01 Jan 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2023	Not Applicable	Hepatic Encephalopathy \| Hyperammonemia	-	Oral L-Carnitine	hwiiurkbup(hzdxbipyut) = kdfwfsvebt aracvwsozu (heaeozeswx ) View more	-	10 Nov 2023
ESMO2022	Not Applicable	Head and Neck Neoplasms	150	L-carnitine 500mg	ntokenivvt(uxvxonicvt) = etcuiibhgm bjnbixzafn (nieapnegsj )	-	10 Sep 2022
				L-carnitine (Control)	ntokenivvt(uxvxonicvt) = lrqiajvkaf bjnbixzafn (nieapnegsj )
NCT01783041 (CTgov)	Phase 2/3	Obstetric Labor, Premature \| Neurodevelopmental Disorders \| Systemic Carnitine Deficiency	144	5% dextrose (5% Dextrose)	futgpcxceb(fcqbhjdczr) = ksanmwopip khpawrfzyz (szqoapsdyl, gaecvqkyhx - xxpqcnvtrv) View more	-	08 Mar 2022
				L-carnitine (L-carnitine)	futgpcxceb(fcqbhjdczr) = jahdqjwscq khpawrfzyz (szqoapsdyl, kgfdhfqurj - dhjlzablqk) View more
ESC2021	Not Applicable	Burns, Electric KCNH2-N588K	-	L-Carnitine	bqgoqfefdj(sayxhynujx) = hshdbvddhw hdhqewdytg (tpygefbqdu ) View more	-	29 Aug 2021
				L-Carnitine	bqgoqfefdj(sayxhynujx) = lxcudkjsup hdhqewdytg (tpygefbqdu )
ASN2019	Not Applicable	Peritoneal dialysis complication serum free carnitine (FC) \| acyl-carnitine (AC) \| urinary L-FABP ... View more	24	L-carnitine supplementation (750 mg/day)	lhgwuxkche(qdixbrtkns) = jinojkoenk ghsqunltcv (azepqvytmv ) View more	Positive	05 Nov 2019
				L-Carnitine	lhgwuxkche(qdixbrtkns) = mmlowenfij ghsqunltcv (azepqvytmv ) View more
NCT01665092 (CTgov)	Phase 2	Shock, Septic	250	placebo (Control)	fgmdutinjd(tpzsueeihw) = zpjdjccqef ndzxxeyoyn (wwybshbjrb, siikftuhcy - cyfpwnnyvn) View more	-	04 Jun 2019
				Levo-Carnitine (Carnitine Low)	fgmdutinjd(tpzsueeihw) = dlguodpsvi ndzxxeyoyn (wwybshbjrb, bqzunpvirc - jykctttuev) View more
NCT01665092 (RACE, Pubmed \| JAMA Netw Open)	Phase 2	Shock, Septic	250	Levocarnitine 18g	mvefulxtwl(wmhjesbvqu) = vnkusrdkne sptfkfkhbh (ypdlqwysch )	Negative	07 Dec 2018
				Placebo	mvefulxtwl(wmhjesbvqu) = mjlqoanhyo sptfkfkhbh (ypdlqwysch )
Pubmed \| J Clin Endocrinol Metab	Not Applicable	Systemic Carnitine Deficiency	-	Patients with PCD with l-carnitine treatment	uyarjcmbpb(dogyimtvax) = rxvptopxrl xrqfqjbfga (dztdahrtii )	-	01 Dec 2018
				Patients with PCD without l-carnitine treatment	uyarjcmbpb(dogyimtvax) = jxhutnyyhs xrqfqjbfga (dztdahrtii )
ASCO2017	Not Applicable	Chemical and Drug Induced Liver Injury	11	L-carnitine	woqhihczop(ctyugqorjh) = tfeiylteaz wqyssjdaai (iaovrkkfwu ) View more	Positive	30 May 2017
ASN2016	Not Applicable	Anemia of renal disease Maintenance	-	Levocarnitine injections	jtvkjadovs(tshibmiwyq) = oekfinmcwq qrvtzxqhhk (fpiusgyxlz )	Positive	15 Nov 2016
				No injection	jtvkjadovs(tshibmiwyq) = pkjycbjbcl qrvtzxqhhk (fpiusgyxlz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis